Cite
HARVARD Citation
Okamura, R. et al. (2020). ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer. 8 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Okamura, R. et al. (2020). ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer. 8 (1), p. . [Online].